跳至主要内容
临床试验/IRCT20220111053692N17
IRCT20220111053692N17招募中Unknown

Bioequivalence study of Empagliflozin Metformin 12.5-1000 mg (Tehran chemie Pharmaceutical Company) versus Synjiardy (Boehringer Ingelheim) Tablet after single oral dosing in healthy volunteers

Tehran Chemie Pharmaceutical Company0 个研究点目标入组 24 人开始时间: 待定最近更新:
适应症

试验速览

阶段
Unknown
状态
招募中
发起方
入组人数
24

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 55 years(—)
性别
Male

入选标准

  • Being at the age of 18 to 55 years old.
  • Weight in range of 10 % of proper body weight.
  • All volunteers should be in a good health condition on the basis of medical history, physical examination, routine blood test.
  • Possessing negative test for hepatitis B surface antigen (HBs-Ag), Antihepatitis-C antibody (anti-HCV) and anti-HIV.

排除标准

  • Volunteers with hypersensitivity to Empagliflozin metformin
  • Those with known history of drug abuse, alcohol consuming or cigarette smoking.
  • Taking medications that have drug interactions with Empagliflozin metformin until one month before studying.
  • Disinclination to take the test.
  • Blood donation or blood loss of more than 200 ml in the past month.

研究者

发起方
Tehran Chemie Pharmaceutical Company

相似试验

Bioequivalence study of Empagliflozin Metformin... | 临床试验